Alphatec Holdings, Inc. reported a 43% increase in fourth-quarter revenue, reaching $106 million. The adjusted fourth-quarter EBITDA margin improved by 750 basis points year-over-year.
Expanded lateral procedural sophistication with PTP and LTP the strongest contributors to Q4 and full year revenue growth
Drove a 26% increase in surgical volume and an 18% increase in average revenue per procedure in Q4
Trained over 500 surgeons in 2022, contributing to a 22% increase in surgeon users compared to prior year
Secured non-dilutive capital creating access to cash and liquidity of up to $275 million
The Company continues to expect total revenue for the fiscal year ended December 31, 2023, to approximate $438 million, reflecting growth of approximately 25% compared to 2022. The Company expects to achieve non-GAAP adjusted EBITDA break-even for the full-year 2023.
Analyze how earnings announcements historically affect stock price performance